|Bid||8.80 x 4000|
|Ask||10.25 x 800|
|Day's range||9.15 - 9.83|
|52-week range||2.23 - 12.22|
|Beta (3Y monthly)||2.34|
|PE ratio (TTM)||N/A|
|Earnings date||29 Oct 2019 - 4 Nov 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||12.69|
ArQule (ARQL) delivered earnings and revenue surprises of 11.11% and -80.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.
ArQule, Inc. today announced that Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the BTIG Biotechnology Conference on Monday, August 12, 2019 at The St.
ArQule (ARQL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ArQule, Inc. (ARQL) today announced it will report financial results for the second quarter of 2019 before the market opens on Wednesday, August 7, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.
ArQule, Inc. (ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,387,500 shares at the public offering price of $9.75 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by ArQule to 10,637,500 shares and increased the gross proceeds raised in the offering, before deducting underwriting discounts and commissions and estimated expenses of the offering payable by ArQule, to approximately $103.7 million. SVB Leerink and RBC Capital Markets acted as joint bookrunning managers for the offering.
ArQule, Inc. (ARQL) today announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.75 per share. ArQule has granted the underwriters a 30-day option to purchase up to an additional 1,387,500 shares of its common stock. The gross proceeds to ArQule from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $90.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by ArQule.
ArQule, Inc. (ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, ArQule expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by ArQule.
ArQule, Inc. (ARQL) today announced that Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 at 8:00 a.m. ET at the The Mandarin Oriental New York, New York. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.
ArQule, Inc. (ARQL) today announced preliminary results from the company’s phase 1/2 study of its pan-AKT inhibitor, miransertib (ARQ 092), in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation at the European Society of Human Genetics Conference in Gothenburg, Sweden.
ArQule, Inc. (ARQL) today announced preliminary results from the Company’s phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the 2019 European Hematology Association (EHA) Annual Meeting in Amsterdam, the Netherlands.
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...